Journal

Data on the safety of psoriasis therapies

Read time: 1 mins

Published:31st May 2014

Author: Leonardi CL.

Source: Seminars in Cutaneous Medicine and Surgery

Availability: Free full text

Ref.:Semin Cutan Med Surg. 2014 Jun;33(4 Suppl):S73-5.

DOI:10.12788/j.sder.0099

Data on the safety of psoriasis therapies

Safety remains paramount to the clinical utility of a therapy. Evaluation of safety is an ongoing process that does not end when a therapy becomes commercially available. This article reviews recent data pertaining to the safety profile of two therapeutic classes widely used in the treatment of psoriasis: inhibitors of tumor necrosis factor-α and agents that target interleukin-12/23.

Read abstract on library site Access full article